Home > Insider Trading > Filing (0001415889-24-001831)

Filing Details

Accession Number:: 0001415889-24-001831
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-25 20:00:34
Reporting Period:: 2024-01-23

Accepted Time:: 2024-01-25 20:00:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1534133	Calcimedica Inc.	CALC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1267959	A Fred Middleton	C/O Calcimedica, Inc. 505 Coast Blvd. S. #307 La Jolla CA 92037		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-23	243,356	$3.70	946,744	No	4	P	Indirect	By Sanderling Venture Partners VI, LP
Common Stock	Acquisiton	2024-01-23	144,676	$3.70	727,433	No	4	P	Indirect	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock	Acquisiton	2024-01-23	194,472	$3.70	435,148	No	4	P	Indirect	By Sanderling Ventures VII, L.P.
Common Stock	Acquisiton	2024-01-23	51,032	$3.70	114,260	No	4	P	Indirect	By Sanderling Ventures VII (Canada), L.P.
Common Stock	Acquisiton	2024-01-23	13,184	$3.70	27,609	No	4	P	Indirect	By Sanderling Ventures VII Annex Fund, L.P.
Common Stock	Acquisiton	2024-01-23	3,920	$3.70	21,602	No	4	P	Indirect	By Sanderling Ventures Management VI
Common Stock	Acquisiton	2024-01-23	28,744	$3.70	30,292	No	4	P	Indirect	By Sanderling Ventures Management VII

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Sanderling Venture Partners VI, LP
No	4	P	Indirect	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
No	4	P	Indirect	By Sanderling Ventures VII, L.P.
No	4	P	Indirect	By Sanderling Ventures VII (Canada), L.P.
No	4	P	Indirect	By Sanderling Ventures VII Annex Fund, L.P.
No	4	P	Indirect	By Sanderling Ventures Management VI
No	4	P	Indirect	By Sanderling Ventures Management VII

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant	Acquisiton	2024-01-23	121,678	$0.13	121,678	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	121,678	$0.13	121,678	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	72,338	$0.13	72,338	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	72,338	$0.13	72,338	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	97,236	$0.13	97,236	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	97,236	$0.13	97,236	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	25,516	$0.13	25,516	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	25,516	$0.13	25,516	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	6,592	$0.13	6,592	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	6,592	$0.13	6,592	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	1,960	$0.13	1,960	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	1,960	$0.13	1,960	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	14,372	$0.13	14,372	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	14,372	$0.13	14,372	$7.15

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
121,678	2024-01-23	2024-12-31	No	4	P	Indirect
121,678	2024-01-23	2026-12-31	No	4	P	Indirect
72,338	2024-01-23	2024-12-31	No	4	P	Indirect
72,338	2024-01-23	2026-12-31	No	4	P	Indirect
97,236	2024-01-23	2024-12-31	No	4	P	Indirect
97,236	2024-01-23	2026-12-31	No	4	P	Indirect
25,516	2024-01-23	2024-12-31	No	4	P	Indirect
25,516	2024-01-23	2026-12-31	No	4	P	Indirect
6,592	2024-01-23	2024-12-31	No	4	P	Indirect
6,592	2024-01-23	2026-12-31	No	4	P	Indirect
1,960	2024-01-23	2024-12-31	No	4	P	Indirect
1,960	2024-01-23	2026-12-31	No	4	P	Indirect
14,372	2024-01-23	2024-12-31	No	4	P	Indirect
14,372	2024-01-23	2026-12-31	No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,714	Direct
Common Stock	8,176	Indirect	By Golden Triangle Ventures, LLC

Footnotes

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.